Mark Mortenson, Chief Science Officer, Clene Nanomedicine is combining physics with biology to develop its bioenergetic nanocatalyst drug candidates that accelerate neurorepair for patients with neurodegenerative disease. Using gold nanocrystals, the company is able to amplify bioenergetic reactions in patients that ultimately drive intracellular biological reactions. The company’s lead candidate, CNM-Au8, is a bioenergetic nanocatalyst powered to support critical intracellular biological reactions that repair and reverse neuronal damage resulting from neurodegenerative disease such as chronic optic neuropathy in patients with multiple sclerosis and the disease progression in patients with ALS.